A Case of Hemolytic Uremic Syndrome in a Lung Cancer Patient Treated with Gemcitabine / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 207-211, 2012.
Article
in Korean
| WPRIM
| ID: wpr-154555
ABSTRACT
Hemolytic uremic syndrome (HUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS arises from a wide spectrum of conditions, and chemotherapeutic agents have been reported to be associated with HUS, including Mitomycin, Cisplatin, Bleomycin, and Gemcitabine. A 76-year-old man treated with Gemcitabine due to non-small cell lung cancer developed clinical and laboratory findings compatible with HUS. Gemcitabine was ceased and hemodialysis and plasma exchange were utilized and he recovered. A high level of suspicion for HUS is necessary when cancer patients are treated with Gemcitabine, and prompt recognition and treatment are also essential.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasma Exchange
/
Thrombocytopenia
/
Bleomycin
/
Renal Dialysis
/
Cisplatin
/
Mitomycin
/
Carcinoma, Non-Small-Cell Lung
/
Deoxycytidine
/
Acute Kidney Injury
/
Hemolytic-Uremic Syndrome
Limits:
Aged
/
Humans
Language:
Korean
Journal:
Tuberculosis and Respiratory Diseases
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS